After controversial approval, doctors are still debating how to use Biogen’s Alzheimer’s drug

BIOPHARMA DIVE (08/03/2021) – The drug, known scientifically as aducanumab and commercially as Aduhelm, has been a source of hope to Alzheimer's patients and their caregivers for the past several years. Rather than treat symptoms of the disease, Aduhelm is meant to address what's considered to be an underlying cause. Full story »

CMS Releases FY 2022 IRF PPS Final Rule

RCPA (07/30/2021) – On July 20, 2021, the Centers for Medicare and Medicaid Services (CMS) issued the fiscal year (FY) 2022 inpatient rehabilitation facility prospective payment system (IRF PPS) final rule. Full story »

COVID-19 May Hasten Alzheimer’s Symptoms

being patient (07/29/2021) – New research suggests that certain Alzheimer’s blood biomarkers are associated with neurological symptoms of COVID-19 and older adults infected with SARS-CoV-2, the virus that causes COVID-19, often experience persistent cognitive impairment. Full story »

CMS’ Proposal to Expand Telehealth Coverage

JD Supra (07/28/2021) – On July 13, 2021, the Centers for Medicare & Medicaid Services (“CMS”) unveiled a proposal to temporarily extend Medicare coverage for particular telehealth services granted during the COVID-19 public health emergency (the “Pandemic”), in order to evaluate which services should be covered permanently. Full story »

Respiratory Vendors See Surge in Business, But SNFs Must Pay (Mostly) Out-of-Pocket

Skilled Nursing News (07/25/2021) – Respiratory service vendors have seen a boom in business due to the pandemic, with respiratory therapists sometimes filling in when COVID unit staff on a nursing home campus became scarce. Full story »

Too much coffee can cause your brain to shrink, raise dementia risk by 53 percent!

Study Finds (07/24/2021) – Drinking six or more cups a day was linked with a 53 percent increased risk of dementia and make stroke more likely, too. Brain imaging reveals that drinking a lot of coffee was also associated with brain shrinkage, say scientists. Full story »

Biogen’s controversial Alzheimer’s drug generates $2 million sales in first few weeks after approval

CNBC (07/23/2021) – Biogen’s Alzheimer’s drug, Aduhelm, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-quarter earnings along with an open letter about the controversial drug. Full story »

The hard math on the new $56,000 Alzheimer’s drug

cnn (07/20/2021) – The US Food and Drug Administration granted maker Biogen special approval despite concerns regarding evidence about how well the drug, technically called aducanumab, even works Full story »

1 2 3 403